MHRA issues alert over Braille labelling omission
A batch of Ocumont Eye Ointment 1% w/w has been distributed without Braille on its outer packaging, prompting an alert from the Medicines and Healthcare products Regulatory Agency (MHRA).
The ointment is used to treat acute bacterial conjunctivitis.
The affected batch (B0866), manufactured by Blumont Pharma Limited, was first distributed on 10 March 2025 and has an expiry date of 30 November 2028.
It is the only batch of the product known to be affected by the omission, which the company says occurred during the approval and release process.
According to the MHRA notice, healthcare professionals are advised to be aware that the product’s packaging is not accessible for patients with visual impairments and to offer appropriate support when dispensing.
The quality and safety of the ointment are not affected by the labelling issue, and no recall is being initiated. No action is required from patients.
Keep your clinical knowledge up to date with The Pharmacist
Extend your learning and record your learning outcomes
Have your say
Please add your comment in the box below. You can include links, but HTML is not permitted. Please note that comments are not moderated before publication and the views expressed are those of the user and do not reflect the views of The Pharmacist. Remember that submission of comments is governed by our Terms and Conditions. You can also read our full guidelines on article comments here – but please be aware that you are legally liable for any libellous or offensive comments that you make. If you have a complaint about a comment or are concerned that a comment breaches our terms and conditions, please use the ‘Report this comment’ function to alert our web team.